JUL 29, 2021
Insurers Promote Use of Untested Biosimilars In The Eye
Some insurance companies are starting to recommend the off-label use of two untested biosimilars — Zirabev from Pfizer and Mvasi from Amgen — as alternatives to Avastin for patients who need anti-VEGF treatment in their eyes.